Interview with Carlos Gallardo, General Manager UK & Ireland, Almirall UK
The UK is leading the biotech turn, and is recognized as the largest biotech market in Europe. Why did Almirall only decide to enter this market until late 2007? Almirall…
Address: 1 The Square
Stockley Park
Uxbridge
Middlesex
UB11 1TD
Tel: +44 (0) 20 7160 2500
Web: http://www.almirall.com/webcorp2/cda/index.jsp
Almirall is an international pharmaceutical company based on innovation and committed to health, headquartered in Barcelona, Spain. Almirall researches, developes, produces and markets proprietary R&D medicines and those under licence with the aim of improving people’s health and wellbeing.
The therapeutic areas on which Almirall focuses its research resources are related to the treatment of:
x Asthma,
x COPD (Chronic Obstructive Pulmonary Disease),
x Rheumatoid arthritis,
x Multiple sclerosis,
x Psoriasis,
x Dermatology
The UK is leading the biotech turn, and is recognized as the largest biotech market in Europe. Why did Almirall only decide to enter this market until late 2007? Almirall…
Lord Philip Hunt, a former UK health minister during the Blair and Brown governments, shares his thoughts on procurement in healthcare, structural change and its impact, and how funds may…
British consultant, speaker and author, Richard Barker – a key opinion leader on UK healthcare – gives his take on the recently launched ‘Life Sciences Industrial Strategy’, the importance of…
Warwick Smith, director general of the British Generic Manufacturers Association (BGMA), discusses the potential impact of Brexit and recent policy changes on the British generics industry and extols the benefits…
Simon Gillespie of the British Heart Foundation (BHF), the UK’s leading national heart charity, outlines the organization’s mission, the issues surrounding translational research, and the potential impact of Brexit on…
Hilary Evans of Alzheimer’s Research UK (ARUK), the UK’s leading national research charity in the field of dementia, discusses her organization’s mission; the growing awareness of, and investment in, dementia…
UK pharmaceutical and biotech companies are already finding it increasingly difficult to attract talent from overseas. Additionally, UK firms are looking to poach EMA staff as it heads to Amsterdam…
Belén Garijo, global CEO of Merck Healthcare, speaking this month at the FT Global Pharmaceutical and Biotechnology Conference, ‘Thriving Amid Uncertainty’, in London, underlined the significance of Merck’s new deal…
Hamid Yunis, partner and head of healthcare at the London office of international law firm, McDermott Will & Emery, discusses the potential negative impact of Brexit and the UK leaving…
Among the assorted pharma CEOs and KOLs gathered at the recent Financial Times Pharmaceutical and Biotechnology Conference in London, debate raged on the pros and cons of a pure play strategy, focusing…
In an exclusive interview at the eyeforpharma Barcelona Summit 2016, Janssen EMEA’s Jane Griffiths speaks out about patient-centricity, sustainability and the dawning of a new world of healthcare. What’s been keeping you…
In an exclusive interview at the eyeforpharma Barcelona Summit 2016, GSK’s Danie Du Plessis speaks out about patient-centricity and the growing role of medical affairs in the pharma industry. In your…
As the head of Eisai’s European operations, how would you assess the relevance of the European market for Eisai’s global operations when compared to the US or emerging markets? Gary…
See our Cookie Privacy Policy Here
